| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Unité Interactions entre Systèmes Protéiques et Différenciation dans la Cellule Tumorale, UPRES-A CNRS 6032, Université dAix-Marseille I et II, Faculté de Pharmacie, 13385 Marseille; and INSERM U-387 (J.-C.L.), 13009 Marseille, France
Address all correspondence and requests for reprints to: Dr. Jacques Marvaldi, Laboratoire de Biochimie Cellulaire, UPRES-A CNRS 6032, Faculté de Pharmacie, 27 boulevard Jean Moulin, 13385 Marseille Cedex 05, France. E-mail: marvaldi{at}newsup.univ-mrs.fr
To investigate endoproteolytic processing of the type I insulin-like
growth factor receptor (IGF-IR), we have examined its structure and
activity in the furin-deficient LoVo-C5 cell line. Immunoprecipitation
experiments using the monoclonal anti-IGF-IR antibody (
-IR3) showed
that LoVo-C5 cells expressed a major high molecular mass receptor (200
kDa) corresponding to the unprocessed
/ß pro-receptor. A small
amount of successfully cleaved
/ß heterodimers was also produced,
indicating a residual endoproteolytic cleavage activity in these cells.
In vitro, a soluble form of recombinant furin was able
to cleave the pro-IGF-IR (200 kDa) into
-subunit (130 kDa) and
ß-subunit (97 kDa). Measurement of IGF binding parameters in LoVo-C5
cells indicated a low number of typical type I IGF-binding sites
(binding capacity, 5 x 103 sites/cell;
Kd, 1.9 nM for IGF-I and 7.0 nM for
IGF-II). These findings in LoVo-C5 contrast with those in HT29-D4
cells, which have active furin, and where IGF-IR (2.8 x
104 sites/cell) was fully processed. Moreover, the 200-kDa
pro-IGF-IR of LoVo-C5 was unable to induce intracellular signaling,
such as ß-subunit tyrosine autophosphorylation and insulin-related
substrate-1 tyrosine phosphorylation. Flow immunocytometry analysis
using
-IR3 antibody indicated that LoVo-C5 cells expressed 40% more
receptors than HT29-D4 cells, suggesting that in LoVo-C5 cells only the
small amount of mature type I IGF-IR binds IGFs with high affinity. To
provide evidence for this idea, we showed that mild trypsin treatment
of living LoVo-C5 cells partially restored
/ß cleavage of IGF-IR,
and greatly enhanced (6-fold) the IGF-I binding capacity of LoVo-C5
cells, but did not restore IGF-IR signaling activity. Moreover, LoVo-C5
cells were totally unresponsive to IGF-I in terms of cell migration, in
contrast to fully processed IGF-IR-HT29-D4 cells. Our data indicate
that furin is involved in the endoproteolytic processing of the IGF-IR
and suggest that this posttranslational event might be crucial for its
ligand binding and signaling activities. However, our data do not
exclude that other proprotein convertases could participate to IGF-IR
maturation.
This article has been cited by other articles:
![]() |
B. K. McColl, K. Paavonen, T. Karnezis, N. C. Harris, N. Davydova, J. Rothacker, E. C. Nice, K. W. Harder, S. Roufail, M. L. Hibbs, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2 FASEB J, April 1, 2007; 21(4): 1088 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Bassi, R. Lopez De Cicco, J. Cenna, S. Litwin, E. Cukierman, and A. J.P. Klein-Szanto PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression Cancer Res., August 15, 2005; 65(16): 7310 - 7319. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Qiu, A. Basak, M. Mbikay, B. K. Tsang, and A. Gruslin Role of pro-IGF-II processing by proprotein convertase 4 in human placental development PNAS, August 2, 2005; 102(31): 11047 - 11052. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kawashima, S. Kanzaki, F. Yang, T. Kinoshita, K. Hanaki, J.-i. Nagaishi, Y. Ohtsuka, I. Hisatome, H. Ninomoya, E. Nanba, et al. Mutation at Cleavage Site of Insulin-Like Growth Factor Receptor in a Short-Stature Child Born with Intrauterine Growth Retardation J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4679 - 4687. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. de Cicco, J. C. Watson, D. E. Bassi, S. Litwin, and A. J. Klein-Szanto Simultaneous Expression of Furin and Vascular Endothelial Growth Factor in Human Oral Tongue Squamous Cell Carcinoma Progression Clin. Cancer Res., July 1, 2004; 10(13): 4480 - 4488. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Duckert, S. Brunak, and N. Blom Prediction of proprotein convertase cleavage sites Protein Eng. Des. Sel., January 1, 2004; 17(1): 107 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Bassi, H. Mahloogi, R. Lopez De Cicco, and A. Klein-Szanto Increased Furin Activity Enhances the Malignant Phenotype of Human Head and Neck Cancer Cells Am. J. Pathol., February 1, 2003; 162(2): 439 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Croissandeau, A. Basak, N. G. Seidah, M. Chretien, and M. Mbikay Proprotein convertases are important mediators of the adipocyte differentiation of mouse 3T3-L1 cells J. Cell Sci., March 15, 2002; 115(6): 1203 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Bassi, R. L. De Cicco, H. Mahloogi, S. Zucker, G. Thomas, and A. J. P. Klein-Szanto Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells PNAS, August 17, 2001; (2001) 191199198. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Khatib, G. Siegfried, A. Prat, J. Luis, M. Chretien, P. Metrakos, and N. G. Seidah Inhibition of Proprotein Convertases Is Associated with Loss of Growth and Tumorigenicity of HT-29 Human Colon Carcinoma Cells. IMPORTANCE OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) RECEPTOR PROCESSING IN IGF-1-MEDIATED FUNCTIONS J. Biol. Chem., August 10, 2001; 276(33): 30686 - 30693. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Bassi, R. Lopez De Cicco, H. Mahloogi, S. Zucker, G. Thomas, and A. J. P. Klein-Szanto Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells PNAS, August 28, 2001; 98(18): 10326 - 10331. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |